Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Cross-border Disputes

Foreign claimant procedural rights in Russian litigation in the pharmaceuticals sector: key developments in 2026

Vitaliy Vetrov · January 2026 · 10 min read

Russian procedural rules governing foreign pharmaceutical claimants shifted in early 2026. What in-house counsel needs to know now. Make an enquiry.

The opening weeks of 2026 have brought renewed attention to the procedural position of foreign claimants in Russian state courts — and for in-house counsel at international pharmaceutical companies, the developments are both material and, in some respects, unexpected. Russian commercial courts, the arbitrazh court system, have in recent years applied the procedural provisions governing foreign participants with increasing consistency. Early 2026 practice signals that sector-specific factors in pharmaceutical disputes are now shaping how those provisions are applied in practice, from the initial filing of a claim through to the enforcement of judgments.

§ I. What changed — the procedural landscape in early 2026

The procedural framework governing foreign claimants in Russian commercial litigation is established in the arbitrazh procedure legislation and has, at its core, provided formally equal procedural rights to foreign and Russian parties before Russian commercial courts. In practice, however, a gap between formal equality and procedural experience has persisted — particularly for foreign pharmaceutical companies engaging the Russian courts for the first time.

The most significant development in early 2026 is the sharpening of documentary verification requirements applied to foreign legal persons initiating proceedings. Before a foreign claimant's claim is accepted and proceedings formally opened, the Russian court requires confirmation of the claimant's legal status and the authority of its representative. This has always been a feature of Russian commercial procedure. What has changed is the standard of verification being applied in pharmaceutical sector matters specifically: courts have in practice begun requiring that documentary confirmation be apostilled and accompanied by a notarised Russian translation prepared within a defined period before the filing date. Translations produced more than six months prior to the filing date have, in a number of first-instance matters in 2025–2026, been returned as procedurally insufficient, requiring refiling.

For foreign companies whose corporate documentation is prepared annually at a fixed calendar date — a common pattern for European and US pharmaceutical groups — this creates a structural mismatch. Documents prepared at the end of the prior financial year may fall outside the six-month window by the time litigation becomes necessary mid-year.

A second development concerns the procedural treatment of pharmaceutical-specific evidentiary materials: registration certificates, clinical data summaries, and intellectual property licences that form the substantive basis of many pharmaceutical disputes. Russian commercial courts have, in the period under review, applied heightened scrutiny to the admissibility of such materials when submitted by foreign claimants, requiring that each document be formally identified in the claim particulars and that its evidentiary purpose be stated. The practice of appending extensive document bundles without structured identification — common in some foreign litigation systems — is now consistently treated as a deficiency requiring the claimant to supplement its materials, extending the pre-hearing phase.

In-house counsel managing a Russian pharmaceutical dispute remotely should treat the pre-filing documentation audit as a substantive step, not an administrative formality. A documentation deficiency identified after the claim is filed costs time that may not be recoverable within the applicable limitation period.

For in-house counsel managing a pharmaceutical dispute before Russian courts — make an enquiry: info@vetrovpartners.com |

§ II. Which foreign pharmaceutical claimants are most affected?

The procedural developments described above affect foreign claimants unevenly, and the distinction is primarily structural rather than jurisdictional. The companies most exposed are those engaging Russian commercial litigation infrequently — typically as a result of a discrete contractual or IP dispute with a Russian distributor, licensee, or regulatory counterparty — rather than those with established, continuous Russian litigation activity.

Three categories of foreign pharmaceutical claimant are particularly affected.

First: companies enforcing distribution or supply agreements against Russian counterparties. These disputes — commonly arising from payment defaults, territory breaches, or post-termination obligations — require the foreign claimant to establish both its corporate standing and the specific contractual basis of the claim with precision. Where the underlying agreement contains Russian-language annexures that were never formally translated into a court-admissible format, the evidentiary preparation required before filing is substantial.

Second: intellectual property holders seeking to enforce trademark rights or challenge a parallel import arrangement. The Russian IP Court handles these matters at first instance on cassation, but the procedural entry point is typically the arbitrazh court. The requirement to produce registration certificates and licensing chain documentation in apostilled, notarised form is applied strictly, and any gap in the licensing chain — even where commercially obvious — requires formal documentary completion before the claim will be accepted without reservation.

Third: foreign claimants in regulatory disputes — for example, where a foreign pharmaceutical company challenges a Russian regulatory authority's decision affecting its product registration or market access rights. These proceedings involve not only commercial procedure but also the administrative court system, and the procedural position of a foreign claimant in administrative proceedings carries additional complexity that commercial procedure alone does not address.

"The pharmaceutical sector has, for procedural purposes, become one of the more demanding environments for a foreign claimant in Russian litigation — not because the rights have narrowed, but because the verification standards have risen while the underlying documents remain governed by foreign law." — Vitaliy Vetrov, Managing Partner, Vetrov & Partners

A further consideration for all three categories is jurisdictional risk. Under Russian civil procedure and arbitrazh procedure principles, a foreign company's choice of Russian court jurisdiction — whether express (in a contract) or implied (by prior conduct) — has procedural consequences for the admissibility of certain interlocutory applications. The courts have in recent practice given limited weight to jurisdictional objections raised late in proceedings by defendants, which may benefit a foreign claimant; but the same principle has also been applied to restrict the foreign claimant's ability to amend its jurisdictional basis after the claim is filed. Getting the jurisdictional framing right at the outset is therefore more consequential than it has previously been.

If you are a foreign pharmaceutical company considering or already engaged in Russian litigation — request our practice review: info@vetrovpartners.com |

§ III. What should foreign pharmaceutical companies do now?

The practical response to these developments is largely pre-litigation in character. For in-house counsel, the most effective mitigation is a structured documentation audit conducted before any dispute reaches the point of filing.

The following steps reflect the current procedural environment.

Verify the currency of corporate confirmation documents. Legal status certificates and equivalent documentation should, as a matter of practice, be refreshed within three months of any anticipated filing date. Annual renewal cycles should be aligned, where possible, with the litigation calendar rather than the financial calendar.Commission notarised Russian translations of all primary claim documents before the matter becomes live. Waiting until the dispute crystallises to commission translations introduces delay and cost at the worst possible moment. Where the dispute concerns IP rights, the registration certificates and any licensing agreements should be translated and apostilled as a standing matter.Conduct a jurisdictional audit of the relevant contracts. Where a contract contains a Russian arbitrazh court jurisdiction clause, confirm that the clause is properly formed under Russian procedural requirements. Defective jurisdiction clauses in pharmaceutical supply and distribution agreements have been the basis for preliminary objections that delay rather than defeat a claim, but the delay is material.Identify the evidentiary basis of the claim in document-specific terms. For IP and product registration disputes, map each substantive claim to the specific document that supports it. Russian courts do not apply a discovery or disclosure process: the documents the foreign claimant needs must be in the claimant's possession and formally identified at the point of filing.Instruct Russian-qualified counsel at the earliest stage. The interface between the foreign legal team's assessment and the Russian procedural requirements is where errors most commonly occur. Counsel who are familiar with current arbitrazh court practice in pharmaceutical matters — and specifically with the documentation standards that courts are currently applying — are best placed to manage this interface.

These steps do not resolve all the procedural complexity that a foreign pharmaceutical claimant will encounter. But they address the specific points at which, in early 2026 practice, claims are being delayed or returned for supplementation.

§ IV. Open questions — what remains to be clarified?

Two areas of procedural uncertainty are worth monitoring through the first half of 2026.

The first concerns the application of EAEU procedural arrangements to pharmaceutical claimants headquartered in EAEU member states. Russia is a member of the Eurasian Economic Union, and the EAEU framework includes provisions intended to simplify certain cross-border procedural requirements between member states. The extent to which those provisions interact with — and potentially simplify — the documentary verification requirements described in § I is not yet settled in practice. Courts in different circuits have taken different positions, and the question is likely to be clarified by circuit-level guidance or a higher-court determination within the year.

The second concerns the admissibility of electronically executed foreign documents. A growing proportion of pharmaceutical licensing and supply agreements are executed electronically under foreign law. Russian procedural law does not yet have a fully settled approach to the authentication of such documents for litigation purposes, particularly where the electronic execution standard applied does not correspond to any Russian equivalent. This is a live issue in a number of pending matters across the arbitrazh court system, and the outcome of those matters will shape practice.

For foreign pharmaceutical companies, both areas reinforce the same practical conclusion: early engagement with Russian-qualified counsel, before the procedural timetable begins running, is the more cost-effective course.

Frequently asked questions

Q: What specifically changed in early 2026 for foreign pharmaceutical claimants in Russian courts? A: The primary change is an increase in the documentary verification standard applied at the claim acceptance stage. Russian commercial courts have in practice required that foreign claimant status documents — legal existence certificates, representative authority documents, and primary claim materials such as registration certificates and licensing agreements — be apostilled and accompanied by notarised Russian translations prepared within six months of the filing date. Documents produced earlier than this have been returned for refreshment in a number of first-instance matters. This represents a tightening of the practical standard rather than a change to the formal rule, but the effect on pre-filing preparation is the same.

Q: Which foreign pharmaceutical companies are most affected by these developments? A: The companies most exposed are those that engage Russian litigation infrequently and whose corporate documentation and contractual materials are governed by foreign law. This includes foreign distribution and supply agreement counterparties, IP rights holders enforcing trademark or licensing rights, and companies involved in regulatory disputes touching product registration or market access. EAEU-member companies may benefit from simplified inter-state procedural arrangements in some respects, though this is not yet uniformly applied across Russian court circuits. Companies with continuous, established Russian litigation activity are generally better positioned because their documentation management practices have already adapted to the Russian procedural environment.

Q: What should in-house counsel do now to prepare for potential Russian pharmaceutical litigation? A: The most effective step is a pre-litigation documentation audit conducted before any dispute reaches the filing stage. This means refreshing legal status certificates on a three-month forward-looking cycle rather than an annual one, commissioning notarised Russian translations of core claim documents in advance, auditing the jurisdiction clauses in relevant contracts, and identifying the specific documents that support each substantive claim. Instructing Russian-qualified counsel with current pharmaceutical-sector experience at an early stage is the most direct way to manage the gap between foreign legal team expectations and Russian court requirements. Early instruction is materially less costly than correcting procedural deficiencies after the claim has been filed and the limitation clock is running.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry